The Patient Voice Aotearoa team, with support from 35 patient advocacy groups, today published a full page ad in the Herald calling on the Prime Minister and her government to urgently fund medicines to save the lives of our most vulnerable, defenceless citizens during Covid-19. Myeloma New Zealand are proud to support the open letter, and...Continue Reading

Pharmac will ease restrictions on at least nine cancer drugs, including keytruda for the treatment of advanced melanoma, to reduce hospital visits and cut the risk of highly vulnerable patients catching Covid-19. One senior oncologist has praised the drug buying agency’s swift response, although patient advocates say cancer sufferers will need much more help during...Continue Reading

New Zealanders living with the incurable blood cancer, multiple myeloma, are set to gain access to a new treatment option following the decision by PHARMAC to subsidise REVLIMID® (lenalidomide) for maintenance treatment from Wednesday April 1, 2020 REVLIMID® (lenalidomide) represents New Zealand’s first and only maintenance treatment specifically indicated and reimbursed for those with newly...Continue Reading